FIELD: chemistry; pharmaceuticals.
SUBSTANCE: compounds - analogs of rapamycin, which have the properties of mTOR inhibitors. The compounds selected from the group specified in cl. 1-7 of claim, their pharmaceutically acceptable salts, tautomers, stereoisomers, oxepane isomers and a pharmaceutical composition based on them, inhibiting mTOR. Methods for treating and preventing diseases mediated by mTOR, including cancer, age-related conditions, immune-mediated diseases, as well as the use of such compounds in the manufacture of a drug for the treatment, prevention or reduction of the risk of a disease or condition mediated by mTOR, as well as for the treatment of cancer, age-related condition and immune-mediated disease.
EFFECT: providing mTOR inhibitory compounds that are effective in the treatment and prevention of mTOR-mediated diseases, including cancer, age-related conditions and immune-mediated diseases.
28 cl, 30 tbl, 152 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF BENZISOXAZOLESULFONAMIDE | 2020 |
|
RU2813356C2 |
| AZALACTAM COMPOUNDS AS INHIBITORS OF HPK1 | 2021 |
|
RU2819642C1 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | 2015 |
|
RU2733400C2 |
| 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
| SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
| COMPOUNDS | 2016 |
|
RU2725616C2 |
| CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
